Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marianne Schimpl

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|February 8, 2022
Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer ModelsJon J Winter-Holt, Catherine Bardelle, Elisabetta Chiarparin, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry|August 12, 2024
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug DesignTaylor R Quinn, Kathryn A Giblin, Clare Thomson, et al.
Journal of Medicinal Chemistry|March 8, 2021
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation StrategyJ Willem M Nissink, Sana Bazzaz, Carolyn Blackett, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor ImmunityJeffrey A Boerth, Alex J Chinn, Marianne Schimpl, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
RSC Medicinal Chemistry|June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitorsAnthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|January 16, 2024
Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b InhibitorsAdelphe M Mfuh, Jeffrey A Boerth, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|February 8, 2022
Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer ModelsJon J Winter-Holt, Catherine Bardelle, Elisabetta Chiarparin, et al.
Journal of Medicinal Chemistry|September 12, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal TumorsJason G Kettle, Rana Anjum, Evan Barry, et al.
Journal of Medicinal Chemistry|August 12, 2024
Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug DesignTaylor R Quinn, Kathryn A Giblin, Clare Thomson, et al.
Journal of Medicinal Chemistry|March 8, 2021
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation StrategyJ Willem M Nissink, Sana Bazzaz, Carolyn Blackett, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor ImmunityJeffrey A Boerth, Alex J Chinn, Marianne Schimpl, et al.
Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.
RSC Medicinal Chemistry|June 16, 2025
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitorsAnthony J Metrano, Lucas A Morrill, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|January 16, 2024
Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b InhibitorsAdelphe M Mfuh, Jeffrey A Boerth, Gayathri Bommakanti, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Pageof 5